Medical Policy

This document addresses the use of fecal analysis panels for the diagnosis of intestinal disorders. Fecal analysis may be suggested for people with gastrointestinal symptoms such as indigestion, constipation, diarrhea, gas, bloating or abdominal pain; symptoms that may overlap with a variety of gastrointestinal disorders such as intestinal dysbiosis, irritable bowel, malabsorption or small intestinal overgrowth of bacteria.

Note: For additional information regarding related documents, please see:

• LAB.00037 Serologic Testing for Biomarkers of Irritable Bowel Syndrome (IBS)

Note: For a high-level overview of this document, please see “Summary for Members and Families” below.

Investigational and Not Medically Necessary:

Fecal analysis panels are considered investigational and not medically necessary for all indications, including as a diagnostic test for the evaluation of intestinal dysbiosis, irritable bowel syndrome, malabsorption or small intestinal overgrowth of bacteria.

This document describes clinical studies and expert recommendations, and explains whether fecal analysis panels in the diagnosis of intestinal disorders are clinically appropriate. The following summary does not replace the medical necessity criteria or other information in this document. The summary may not contain all of the relevant criteria or information. This summary is not medical advice. Please check with your healthcare provider for any advice about your health.

Key Information

Fecal analysis panels are stool tests that measure many markers related to digestion, absorption of nutrients, inflammation, immune response, and the balance of bacteria in the gut. They are marketed to help diagnose conditions such as intestinal dysbiosis, irritable bowel syndrome (IBS), malabsorption, and small intestinal bacterial overgrowth. These panels test for things like pancreatic elastase, fecal fats, calprotectin, secretory IgA, short chain fatty acids, and different bacteria or parasites. Some tests also provide scores that suggest an imbalance in gut bacteria. However, these panels have not been proven to accurately diagnose these conditions or to improve health outcomes. There are concerns that using these broad panels may lead to unclear results, unnecessary follow up testing, or treatment that does not help. No major medical groups recommend these stool panels for diagnosing these conditions.

What the Studies Show

Fecal analysis panels examine stool for markers linked to digestion, inflammation, immune activity, and the gut microbiome. The gut microbiome refers to the community of bacteria and other microorganisms that live in the intestines. These panels may include tests for fat in the stool, protein breakdown products, inflammatory markers, and different types of bacteria or yeast. Some laboratories also provide scores that claim to measure bacterial imbalance, also called dysbiosis. Dysbiosis is not clearly defined as a specific disease, and its symptoms, such as bloating, diarrhea, constipation, and abdominal pain, overlap with other digestive conditions. There are no high quality studies showing that fecal analysis panels can accurately diagnose intestinal dysbiosis, IBS, malabsorption, or small intestinal bacterial overgrowth. There are also no high quality studies showing that using these panels leads to better treatment decisions or improved health. Medical groups such as the American Gastroenterological Association (AGA) recommend diagnosing IBS based on symptoms and established criteria. For suspected bacterial overgrowth, they recommend targeted tests such as breath testing or culture of fluid from the small intestine. Because fecal analysis panels have not been proven to improve health, such unnecessary or unproven tests can lead to treatment that does not help. Some treatments, such as antibiotics, may cause side effects including diarrhea, allergic reactions, or changes in normal gut bacteria.

Is this Clinically Appropriate?

Fecal analysis panels are not clinically appropriate for any indication, including evaluation of intestinal dysbiosis, IBS, malabsorption, or small intestinal bacterial overgrowth. They are not appropriate because they have not been proven to accurately diagnose these conditions or to improve health. Better studies are needed to know if fecal analysis panels improve health outcomes. Fecal analysis panels are not clinically appropriate for any indication at this time.

(Return to Description/Scope)

Summary

This document addresses the use of comprehensive fecal analysis panel testing for evaluation of gastrointestinal symptoms and suspected intestinal disorders, including dysbiosis, irritable bowel syndrome (IBS), malabsorption, and small intestinal bacterial overgrowth. These panels assess multiple stool markers related to digestion, absorption, inflammation, and the gut microbiome; however, current evidence does not demonstrate established diagnostic performance or clinical utility for these indications. Major gastroenterology society guidance, including the American Gastroenterological Association (AGA) recommendations, supports clinical criteria and targeted testing (such as breath testing or jejunal culture for bacterial overgrowth) rather than broad fecal panel analysis for these conditions.

Discussion

Intestinal dysbiosis as a specific disorder is poorly defined. The gastrointestinal symptoms attributed to intestinal dysbiosis (for example, bloating, flatulence, diarrhea or constipation) overlap in part with IBS and small intestinal bacterial overgrowth syndrome. The diagnosis of IBS is typically made clinically, based on a set of criteria referred to as the Rome criteria (Lacy, 2017). Small intestine bacterial overgrowth may result from altered motility (including blind loops), decreased intestinal acidity, exposure to antibiotics, or surgical resection of the small bowel. Symptoms include diarrhea, bloating, abdominal pain and, in more severe cases, steatorrhea (Quigley, 2020). Although the diagnosis of bacterial overgrowth may be made clinically and the condition treated empirically with antibiotics, the laboratory diagnosis may consist of culture analysis of a jejunal fluid sample or hydrogen breath testing. Hydrogen breath tests, commonly used to evaluate lactose intolerance, have been adapted for use in diagnosing both small intestinal bacteria overgrowth and irritable bowel disease (Rana, 2014; Quigley, 2020). Chronic intestinal candidiasis has been linked with various gastrointestinal complaints as well as systemic complaints, such as chronic fatigue syndrome. However, chronic intestinal candidiasis is an ill-defined condition without established diagnostic parameters.

Porcari and colleagues (2025) reported on an international multidisciplinary consensus statement that developed standardized recommendations for the clinical provision, interpretation, and reporting of gut microbiome testing, addressing general principles, pre-testing procedures, sequencing methodologies, report characteristics, and future research priorities. Through a structured Delphi process involving 69 experts from 18 countries, the panel emphasized that microbiome testing should be conducted by accredited laboratories with multidisciplinary expertise, use validated sequencing approaches such as amplicon or whole genome sequencing, incorporate appropriate bioinformatic pipelines and diversity metrics, and provide transparent reporting without therapeutic recommendations embedded in the report. The group concluded that although microbiome profiling holds scientific promise, current evidence is insufficient to support routine clinical use, and well-designed diagnostic and interventional studies are needed to demonstrate clinical value.

Literature searches did not identify any published studies regarding the diagnostic performance of fecal analysis of digestion, absorption, microbiology, metabolic markers or immunology as a diagnostic tool for suspected malabsorption syndrome, small intestine bacterial overgrowth or intestinal dysbiosis. Moreover, to date there have not been any high-quality studies linking fecal analysis for intestinal disorders with any specific treatment or other clinical utility.

The symptoms and conditions that have been attributed to intestinal disorders include irritable bowel disease, inflammatory or autoimmune disorders, food allergy, atopic eczema, unexplained fatigue, arthritis and ankylosing spondylitis, malnutrition, breast and colon cancer, and neuropsychiatric symptoms, including autism.

Laboratory analysis of stool using panel testing has been investigated for potential markers of intestinal disorders. These comprehensive panels are intended to address various aspects of digestion, absorption, microbiology and metabolic markers. For example, the Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory Genova Diagnostics (Asheville, NC) offers the GI Effects^® test that evaluates a stool sample for the following components (these components may also be included in other fecal analysis panel tests):

Digestion/Absorption

• Pancreatic elastase-1
• Products of protein breakdown (valerate, isobutyrate, isovalerate)
• Fecal fats (triglycerides, long-chain fatty acids, cholesterol, phospholipids)

Inflammation and Immunology

• Calprotectin
• Eosinophil Protein X
• Fecal Secretory IgA
• Fecal Occult Blood Test

Gut Microbiome:

• Metabolic indicators including short-chain fatty acids and beta-glucuronidase
• Commensal bacteria
• Bacterial and mycology cultures
• Parasitology

Test results include an inflammation-associated dysbiosis score and a methane dysbiosis score.

Other Relevant Information

No Food and Drug Administration (FDA) labeled indications have been identified for fecal analysis tests used in the evaluation of intestinal dysbiosis, irritable bowel syndrome, malabsorption or small intestinal overgrowth of bacteria. No relevant Centers for Medicare and Medicaid Services (CMS) National or Local Coverage Determinations have been identified addressing tests considered in this document. Moreover, no nationally recognized clinical practice guidelines recommend fecal analysis as diagnostic tests for intestinal dysbiosis, irritable bowel syndrome, malabsorption or small intestinal overgrowth of bacteria.

Autoimmune: Disease that results when the immune system mistakenly attacks the body's own tissues.

Intestinal flora: Microorganisms (for example, bacteria) that inhabit the intestinal tract and are essential for its normal functioning.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When Services are Investigational and Not Medically Necessary:
When the code(s) describes a procedure indicated in the Position Statement section as investigational and not medically necessary.

Peer Reviewed Publications:

1. Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med. 2017; 6(11):99.
2. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000; 95(12):3503-3506.
3. Porcari S, Mullish BH, Asnicar F, et al. International consensus statement on microbiome testing in clinical practice. Lancet Gastroenterol Hepatol. 2025; 10(2):154-167.
4. Rana SV, Malik A. Hydrogen breath tests in gastrointestinal diseases. Indian J Clin Biochem. 2014; 29(4):398-405.

Government Agency, Medical Society, and Other Authoritative Publications:

1. Genova GI Effects Comprehensive Profile-Stool. Available at: https://www.gdx.net/products/gi-effects. Accessed on May 1, 2026.
2. Quigley EMM, Murray JA, Pimentel M. AGA clinical practice update on small intestinal bacterial overgrowth: expert review. Gastroenterology. 2020; 159(4):1526-1532.

Comprehensive Digestive Stool Analysis (CDSA)
Comprehensive Gut Health Test
Fecal Analysis in the Diagnosis of Intestinal Dysbiosis
GI Effects Comprehensive Profile
GI-MAP
Intestinal Dysbiosis

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association